Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile

BackgroundBiosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in h...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paul Chamberlain, Bernhard Hemmer, Josef Höfler, Hendrik Wessels, Oliver von Richter, Cyrill Hornuss, Johann Poetzl, Karsten Roth
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	natalizumab multiple sclerosis neutralizing antibodies anti-drug antibodies immunology biologic products
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1414304/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

John Cunningham Virus seroconversion during natalizumab treatment
by: Erica Freire de Vasconcelos-Pereira, et al.
Published: (2024-11-01)

Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2024-11-01)

NEDA-state, psychological symptoms and quality of life are stable in natalizumab-treated multiple sclerosis patients: An up to 6-years long follow-up study
by: Dániel Sandi, et al.
Published: (2024-10-01)

Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity
by: Maeva Katzmarzyk, et al.
Published: (2024-10-01)

Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses
by: Zhenwei Liu, et al.
Published: (2025-01-01)

Immunogenicity of the CoronaVac vaccine in children: a real-world study
by: Wbeimar Aguilar-Jimenez, et al.
Published: (2024-12-01)

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
by: Sophie Tourdot, et al.
Published: (2024-12-01)

A Brief Chronicle of Antibody Research and Technological Advances
by: Kazutaka Araki, et al.
Published: (2024-11-01)

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
by: Ruoxuan Sun, et al.
Published: (2024-12-01)

Testing of Ferarabivac anti-rabies live vaccine for wild carnivores for its immunogenicity and protectivity
by: A. V. Shishkov, et al.
Published: (2020-03-01)

Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01)

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
by: Aimee E. Mattei, et al.
Published: (2024-12-01)

Protocol for measuring anti-fentanyl antibodies in mouse serum by enzyme-linked immunosorbent assay
by: Jacob A. Koster, et al.
Published: (2024-12-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)

Therapeutic proteins immunogenicity: a peptide point of view
by: Feliciana Real-Fernandez, et al.
Published: (2023-10-01)

Determining factor of enzyme conjugates, bridge heterology and analytical variables of immunogens in prednisolone ELISA
by: Dinesh Kumar, et al.
Published: (2024-12-01)

Current methods for detecting and assessing HIV-1 antibody resistance
by: Stanley Odidika, et al.
Published: (2025-01-01)

Protocol for murine multi-tissue deep immunophenotyping using a 40-color full-spectrum flow cytometry panel
by: Pierre Lemaitre, et al.
Published: (2024-12-01)

Protocol for rapid evaluation of antibody-mediated protection in macrophages using immunofluorescence techniques
by: Lingyuan Zeng, et al.
Published: (2024-12-01)

Protective or limited? Maternal antibodies and RSV-associated lower respiratory tract infection in hospitalized infants aged 28-90 days
by: Shuanglian Li, et al.
Published: (2025-01-01)

Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies
by: A. N. Chikaev, et al.
Published: (2021-09-01)

Characterization of two neutralizing monoclonal antibodies with conformational epitopes against porcine deltacoronavirus
by: Wan Lu, et al.
Published: (2025-01-01)

What are clinically significant anti-drug antibodies and why is it important to identify them
by: Steven James Swanson
Published: (2024-12-01)

Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
by: Nicole L. Jarvi, et al.
Published: (2024-12-01)

Preparation and application of porcine broadly neutralizing monoclonal antibodies in an immunoassay for efficiently detecting neutralizing antibodies against foot-and-mouth disease virus serotype O
by: Yimei Cao, et al.
Published: (2025-02-01)

Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy
by: Hongye Wang, et al.
Published: (2025-01-01)

Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains
by: Ana C. B. Terzian, et al.
Published: (2024-11-01)

Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots
by: Katherine Berman, et al.
Published: (2024-12-01)

A Comprehensive Evaluation of the HPV Neutralizing Antibodies in Guangzhou, China: A Comparative Study on Various HPV Vaccines
by: Renyun Zha, et al.
Published: (2024-11-01)

Replacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibody
by: Joleen T. White, et al.
Published: (2024-12-01)

Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
by: Silvia García, et al.
Published: (2024-11-01)

Course of Care of a Multiple Sclerosis Patient in the Context of Pharmacotherapy
by: Anna Smelkowska, et al.
Published: (2015-06-01)

Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity
by: Aboli Bhingarkar, et al.
Published: (2025-01-01)

SARS-CoV-2 infection induces human milk antibodies capable of mediating multiple functional activities
by: Jared Sheehan, et al.
Published: (2024-12-01)

A humanized neutralizing antibody protects against human adenovirus type 7 infection in humanized desmoglein-2 and CD46 double-receptor transgenic mice
by: Chengxing Zhou, et al.
Published: (2024-11-01)

Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient
by: Yanan Wu, et al.
Published: (2024-11-01)

Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023
by: Huan Zhang, et al.
Published: (2024-11-01)

Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies
by: Wenling Jiang, et al.
Published: (2024-12-01)

Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players
by: Aurélien Chepy, et al.
Published: (2025-06-01)